Amidst stalled HIV prevention, WHO supports new long-acting prevention drug cabotegravir
The UN health agency on Thursday recommended the use of a new long-acting “safe and highly effective” prevention option for people at “substantial risk” of HIV infection, known as cabotegravir (CAB-LA).
Read Original Article: Amidst stalled HIV prevention, WHO supports new long-acting prevention drug cabotegravir »
